Australia’s Therapeutic Goods Administration (TGA) issued a safety alert on 5 November 2026 after laboratory testing found that tested Synedica peptide products did not match their labels. The practical issue is uncertainty: a label may not reliably tell someone which substance they are receiving, or how much.
What did the testing show?
No TB-500 was detected in tested Synedica BPC 157 & TB 500 10 mg, KLOW 80 mg or BARBIE KLOW 100 mg products. Tested Synedica Retatrutide 10 mg products contained less retatrutide than the label stated, with significant variation between samples. The amounts in these product names are label claims, not verified contents or recommended doses.
These are findings about the tested products. They do not establish what is in every vial sold under the brand, or show that other unapproved products are safe. “Not detected” is also not a measurement of someone’s individual exposure.
Why does this matter in Australia?
The TGA says Synedica peptide products have not been assessed for quality, safety or effectiveness, and their place of manufacture has not been approved. It warns that peptide products can cause serious side effects, including a major allergic reaction. The alert does not provide a numerical estimate of that risk.
Retatrutide is still being studied in human clinical trials. According to the alert, it has not been approved by the TGA or a comparable international regulator. Products marketed outside a trial should not be confused with a medicine assessed and approved for routine use.
What does the regulator recommend?
The TGA advises people not to use Synedica peptide products, to take remaining product to a pharmacy for safe disposal, and to speak with a health professional about health concerns after use. It also encourages reporting suspected side effects.
If you suspect a severe allergic reaction, use an adrenaline autoinjector if available and call triple zero (000) for an ambulance. Healthdirect’s guide to severe allergic reactions.
What remains uncertain?
This is a regulatory laboratory alert, not a clinical trial. The published notice does not give sample counts, detailed testing methods or exact measured retatrutide concentrations. It cannot tell us how commonly people have been harmed or quantify an individual’s risk.
Prepared with AI assistance from the TGA safety advisory. This article provides general health information.
Primary source
TGA safety alert: testing of Synedica peptide products (5 November 2026). Accessed 8 November 2026 (AEDT).